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Background: In randomized controlled trials, short message service (SMS) programs have improved adherence to
HIV antiretroviral therapy (ART). In response, the World Health Organization recommended use of SMS programs to
support ART. However, there is limited data on real-world implementations of SMS programs.
Methods: We conducted a retrospective cohort study of an SMS program to improve ART adherence in a government-
run HIV clinic in rural South Africa. We analyzed data from all adult patients who 1) enrolled at the clinic
before the observation period (July 2013 through June 2014), 2) had ≥1 ART prescriptions in the observation period,
and 3) had data on phone number availability (N = 2255). Our main outcome measure was prescription coverage,
defined as the presence of a valid ART prescription for each day observed. We fit generalized linear mixed
models adjusted for pre-program prescription coverage, demographics, and ART duration, dosing, and regimen.
Results: Exposure to the SMS program was independently associated with greater prescription coverage
(AOR = 1.23, 95% CI 1.13–1.34, P < 0.001) compared with non-exposure, although the absolute increase
in prescription coverage was small (4.7 days of ART prescription coverage per average patient per year).
Among a subset of patients (n = 725) whose pre-program prescription coverage was <100%, the corresponding mean
expected absolute increase in prescription coverage was 8.2 days per year.
Conclusions: Our primary finding was that an SMS reminder program implemented in routine clinical care
was associated with a small increase in prescription coverage of uncertain clinical significance.
Keywords: HIV, Antiretroviral therapy, South Africa, SMS program, Adherence, Differentiated care, Program
evaluation, Implementation researchBackground
Successful antiretroviral therapy (ART) for HIV depends
on sustained, high adherence [1]. However, adherence
remains a significant challenge for many [2]. Numerous
barriers to adherence exist, which can be broadly catego-
rized as individual (e.g., comorbid psychiatric conditions
and forgetfulness), social (e.g., isolation and stigma), and
systemic (e.g., stock-outs and inadequate counseling) [3].
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Indeed, one qualitative study in sub-Saharan Africa iden-
tified missed appointments as triggers of a cascade of
disengagement from care [5]. In the past several years,
considerable interest has developed in using short mes-
sage service (SMS), or text messaging, to address forget-
fulness; others have also indicated the potential for SMS
to improve the connection between patient and clinic,
along with social isolation [6, 7]. SMS interventions
generally fall into the following categories: daily dose
reminders [8, 9], appointment reminders [10, 11], andle is distributed under the terms of the Creative Commons Attribution 4.0
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herence support, or both [9, 12–14].
Several randomized controlled trials (RCTs) have
investigated the adherence benefits of weekly SMS
programs. They have shown a mix of positive and
null findings in terms of effect on adherence and viral
suppression [12, 13, 15]. However, meta-analyses have
shown an overall positive impact of SMS programs
on adherence. A network meta-analysis of fourteen
RCTs on adherence interventions throughout Africa
found that weekly SMS significantly improved self-
reported adherence and rates of viral suppression,
although evidence was more limited for the latter
finding [16]. Another meta-analysis of similar RCTs
globally found that SMS programs could significantly
improve adherence, and that weekly messaging was
superior to daily [17].
The World Health Organization has recommended
mobile phone text messages as an adherence support
intervention for people on ART [18]. However, to our
knowledge all previous publications report on SMS in-
terventions implemented as part of research studies. Re-
search studies typically provide significant resources to
clinical infrastructure and participants directly, such as
mobile phones [9], and intensive follow-up may alter
behavior compared to routine clinical care. Moreover, it
is difficult to assess an SMS program’s impact on ad-
herence in the context of payments or other incentives
provided for each study visit attended [9, 19]. Thus,
the primary motivation of this work was to assess the
implementation of an SMS program to determine whether
the findings of the RCTs are borne out in a realistic
clinical setting.
In this study, we evaluated a clinical program of
weekly SMS reminders at a government-run HIV clinic
near Durban, South Africa. Using a retrospective cohort
design, we analyzed routine data collected at the clinic
to determine ART prescription coverage, comparing
those who were or were not sent SMS reminders.
Methods
Study population and clinic
This study was conducted at the Ethembeni HIV Clinic,
located in a rural area approximately 40 km from
Durban, South Africa. Ethembeni is a government-run,
hospital-based HIV clinic with an on-site pharmacy,
which provides free ART. The adult clinic population is
approximately 67% female, has a median age of 37 years,
and nearly all speak isiZulu as their first language.
Patients at Ethembeni receive prescriptions of varying
lengths (e.g., one, two, three, or six months of ART at a
time), depending on clinical needs. All prescribed medi-
cations are picked up at the on-site pharmacy. Patients
with a prescription for three or fewer months generallyreceive all prescribed pills during the prescribing visit.
Patients with a six-month prescription generally receive
three months of pills at a time.
SMS adherence program
The SMS adherence program was developed by clinic
staff in collaboration with Sawubona Health (Malden,
MA), a US-based non-governmental organization. Clinic
staff and Sawubona Health volunteers manually entered
mobile phone numbers from paper charts of adult pa-
tients into the SMS program database over two discrete
periods (June-July 2012 and the month of June 2013).
Notably, the clinic routinely asked each patient for a
contact phone number at clinic enrollment, which was
an average of 3.3 (SD 1.5) years prior to the SMS pro-
gram launch date. Patients were not re-approached by
staff to add a phone number for capture into the SMS
program database due to program resource limitations.
The SMS program started on September 9, 2013 and
is ongoing. All SMS are sent free of charge to patients;
the program costs approximately 1 USD per patient per
year to run. The program is opt-out; the first SMS
explaining the program was sent to each adult patient
with a recorded mobile phone number. This introduc-
tory SMS also informs patients how to opt-out, which
can be done at any time via a reply SMS. SMS are sent
to all subscribed patients each week by rotating through
the following message (in isiZulu):
Hi (First name), this is your clinic. Remember to take
your pills on schedule in order to (One of: be strong
or live a long life or feel well). Thank you.
Starting on January 13, 2014, the program server began
receiving delivery status reports of confirmed receipt of
the SMS on the patient’s registered phone number.
Further details on the SMS program can be found in a
separate interview-based evaluation study [20].
Data sources
Data for this analysis was extracted from routinely col-
lected pharmacy and medical record data, as well as the
SMS program data. We utilized data from November 4,
2012 through June 26, 2014, the time period for which
prescription data were available. The dates, duration,
and medications of each prescription were extracted for
all patients at the clinic during this period. The elec-
tronic medical record extraction included age, gender,
ART start date, and date of transfer out (if applicable).
The SMS program data included the availability of a
valid mobile phone number, date the phone number was
available, date of opt-out (if applicable), and delivery
status reports (from January 13 through June 26, 2014).
The datasets were de-identified except for dates and
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(ID). An indicator variable was created which was set to
one for patients with any missing values for any non-
prescription covariates, and set to zero otherwise.
Missing values for non-prescription covariates were
replaced with the mean of all corresponding available
values in the cohort.
Statistical methods
Figure 1 presents a visual timeline of important time pe-
riods related to this analysis. All patients satisfying the
following criteria were included in the study cohort:
1. 18 years or older;
2. At least one ART prescription during the time
for which both pharmacy and mobile phone
data were available – the “observation period”
(July 1, 2013 to June 26, 2014);
3. Enrolled at the clinic on or before July 1, 2013;
4. Phone number availability assessed prior to
the observation period.
Our primary exposure of interest was inclusion in the
SMS program. Clinic patients were assigned to one of
the following analysis groups based on whether data
from their chart had been captured into the SMS pro-
gram database and on potential exposure to the SMS
program (i.e., those who were and were not sent mes-
sages) via an intention-to-treat approach. That is, group
assignment disregarded whether the patients who were
sent messages opted-out or failed to receive the messages
due to phone number change or technical difficulties.
1. “Exposed”: Patients who had a valid mobile phone
number in their chart during the SMS program data
capture process.
2. “Unexposed”: Patients who had a chart available for
review but for whom a valid mobile phone number
was not identified in the chart. This situation could
be because they did not have, or did not choose toFig. 1 Key dates used to define the analysis periodsprovide, a mobile phone number at the time of
enrollment; rare instances of erroneous recording
of the phone number were also noted.
3. “Unknown”: All remaining patients in the cohort,
for whom the presence or absence of a mobile
phone number was not determined due to missing
charts. Common reasons for missing charts were use
of the chart elsewhere in clinic or loss to follow-up.
Each patient was observed for a specific subset of the
observation period, as determined by the following cen-
soring criteria. The first day of the observation period
was July 1, 2013. Within this period, observations began
at the earliest of: 1) the day after the end of the patient’s
first recorded prescription during the pharmacy data
availability period (November 2012 through June 2014),
or 2) the day of the patient’s second recorded prescrip-
tion (to avoid including patients who had not clearly
established care in the clinic). We right-censored pa-
tients on the earlier of their transfer-out date or June 26,
2014 (i.e., the last available day of pharmacy data). For
baseline characteristics, continuous values were com-
pared with ANOVA; categorical values were compared
with the Chi-squared test.
Our primary outcome was ART prescription coverage.
A day was defined as covered if the patient had valid
prescriptions that, if filled and taken as prescribed,
allowed the patient to possess sufficient medication for
the intended three-drug ART regimen on that day;
otherwise, the day was considered not covered. Each day
during the study period was a unit of observation, and
thus each patient was weighted by their length of obser-
vation. The rates of patients achieving > 95% coverage
before versus during the SMS program were compared
using the one-sample McNemar’s test.
The daily unit of observation was chosen because: 1)
several covariates and the outcome varied through time,
and thus averaging these values across extended time
periods would obscure the temporal relationship between
covariates and the outcome; and 2) averages across longer
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could not be adequately modeled by standard distribu-
tions. If a patient had days of prescription coverage
remaining at the time of a new prescription, the remaining
days of coverage were carried over to the next prescrip-
tion, up to a maximum of 30 days per clinic policy, if there
was no change in the antiretrovirals. For example, if a
patient had 15 days of prescription coverage remaining,
and came early to an appointment at which they received
a 30-day prescription for the same antiretrovirals, they
would have 45 days of prescription coverage available.
Any records of prescriptions that simply re-recorded the
remaining balance of a 6-month prescription (e.g., a 3-
month prescription recorded 3 months after a 6-month
prescription) were treated as duplicates.
To account for repeated measures within an indi-
vidual, we used mixed effects multivariable logistic
regression models. No univariable results were deter-
mined; our a priori interest was in the adjusted results as
described below. All models were fit using Stata version
13.1 (StataCorp, College Station, TX, USA).
In the regression model, we determined if SMS pro-
gram exposure was associated with ART prescription
coverage. Fixed effects were study group (i.e., Exposed,
Unexposed, and Unknown), time period (i.e., pre-
program versus during program), and factors available
in the database that have been shown to influence
adherence. Specifically, these factors were age [21],
gender [21], prior duration of ART [21], prescription
duration, first or second-line ART regimen [22], and
fixed-dosed combination ART [23]. The “pre-program
period” was defined as the two months prior to the
start of the SMS program (i.e., July 1 through September
9, 2013), which served as a baseline level of adherence.
We used an interaction term between study group and
time period to determine the effect size of exposure to the
SMS program. The model included a random intercept
at the patient level. We used stepwise backward
elimination (threshold P = 0.25) [24], with the pro-
gram groups, time period, and their interactions
retained a priori, to select the covariates for the exe-
cuted model.
To estimate the absolute risk reduction of SMS pro-
gram, the model calculated the time-averaged prescrip-
tion coverage for the Exposed patients in the during-
program period. We then applied the odds ratio of
coverage given non-exposure during the program (com-
paring the Unexposed and Exposed groups). This calcu-
lation yielded the hypothetical coverage that an average
patient would have had if they had not been exposed to
the SMS program. The difference between the actual
coverage and the hypothetical non-exposure coverage
equaled the absolute risk reduction for a patient with
average coverage.Given the WHO emphasis on providing differentiated
care [18] as well as the possibility that SMS interven-
tions would need to be targeted to at-risk populations to
achieve cost-effectiveness, we examined two subsets of
patients using the same method as that used for the full
cohort.
1. The <100% baseline coverage subset: patients with
pre-program prescription coverage < 100%, suggesting
at least one missed prescription during that period.
2. Recent ART initiators subset: patients who initiated
ART within 2 years of the start of the SMS program,
because such patients have an accelerated rate of





A total of 2,920 patients received ART during the
pharmacy data availability period of November 4,
2012 to June 26, 2014. Of these, 665 did not meet
our inclusion criteria for the following reasons: age
<18 years (N = 458), no ART prescription in the ob-
servation period (N = 33), not enrolled at Ethembeni
prior to the observation period (N = 160), delayed
capture of phone number into the SMS program (N
= 1), and no observation time (e.g., patient trans-
ferred out before end of first prescription) (N = 13).
The study cohort therefore consisted of 2,255 pa-
tients: 1,771 (78.5%) in the Exposed group, 316
(14.0%) in the Unexposed group, and 168 (7.5%) in
the Unknown group. The introductory SMS was sent
to all 1,771 patients in the Exposed group. Among
these patients, 1,287 (72.7%) had at least one
confirmed successful SMS delivery (during the time
this data were available, January 13 through June 26,
2014) and among these, 1,044 (81.1%) remained
subscribed to the program for their entire time of
observation.
Patients included in the full cohort analysis were
similar to the general clinic population in terms of
age and gender (Table 1). The full cohort Exposed
and Unexposed groups were similar except that the
Exposed group was younger and had a greater
proportion of females compared to the Unexposed
group. The Unknown group significantly differed
from the Exposed and Unexposed groups in terms of
several variables. Additionally, missing data was
higher in the Unknown group compared to the Ex-
posed and Unexposed groups. Of note, rates of fixed
dose combination use increased for all groups during
the observation as part of a nationwide rollout of the
formulation.







P-value for all P-value for Exposed
vs. Unexposed
Age in years (IQR) 37.7 (32.4–43.9) 38.9 (33.1–46.6) 37.7 (31.7–42.9) 0.015 0.006
Female 1,253 (70.8%) 203 (64.2%) 117 (69.6%) 0.068 0.020
ART duration in years (IQR) 2.4 (1.5–3.3) 2.5 (1.6–3.5) 2.5 (1.2–3.4) 0.270 0.120
Prescription length in days (IQR) 180 (65–180) 180 (66–180) 90 (36–180) <0.001 0.846
Patients (%) with… <0.001 0.710
1-month prescriptions 227 (12.8%) 43 (13.6%) 48 (28.6%)
2-month prescriptions 282 (15.9%) 48 (15.2%) 24 (14.3%)
3-month prescriptions 234 (13.2%) 35 (11.1%) 18 (10.7%)
6-month prescriptions 1028 (58.0%) 190 (60.1%) 78 (46.4%)
First line regimen 1,675 (94.6%) 295 (93.4%) 151 (89.9%) 0.041 0.383
Fixed dose combination 28 (1.6%) 5 (1.6%) 9 (5.4%) 0.002 0.999
No pre-program observation time 93 (5.3%) 22 (7.0%) 25 (14.9%) <0.001 0.220
Transfer out during observation 61 (3.4%) 8 (2.5%) 9 (5.4%) 0.269 0.507
IQR interquartile range
Values reflect data collection on November 4, 2012 (for age and ART duration) or as of first statistical observation (for all others). Bold indicates statistical
significance (P < =0.05)
Fig. 2 Distribution of per-patient prescription coverage in the full
cohort. Pre-program refers to the two months prior to the start of
the SMS program
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The distribution of prescription coverage by patient
before and during the program period is shown in Fig. 2.
Prescription coverage was right-skewed, with the major-
ity of patients achieving >95% coverage in both periods.
For all three groups, this proportion of patients with
coverage >95% decreased from the pre- to during-
program period; this decrease was 2% (P = 0.277) for the
Exposed group, compared with 6% (P = 0.118) and 13%
(P = 0.038) for the Unexposed and Unknown groups,
respectively.
Effect of SMS program exposure on prescription coverage
in the full cohort
After adjusting for age, gender, prescription lengths, regi-
men type, fixed dose combination, and pre-program pre-
scription coverage, patients in the Exposed group had
greater odds of daily prescription coverage during the SMS
program (AOR 1.23, 95% CI: 1.13–1.34, P < 0.001) com-
pared to those in the Unexposed group. For an Exposed
patient at an average level of adherence (94.1% during the
program), the absolute risk reduction of exposure to the
SMS program was 4.7 days of ART prescription coverage
missed per year compared to the Unexposed group.
Full cohort patients in the Unknown group (compared to
those in the Unexposed group) had higher odds of pre-
program coverage (AOR 1.60, 95% CI: 1.022–2.51, P =
0.040), but after adjustment for this factor, had lower odds
of coverage during the program (AOR 0.47, 95% CI: 0.41–
0.54, P < 0.001). As shown in Table 2, increasing age, female
gender, longer prescription length, use of a first line regi-
men, and use of a fixed dose combination were also associ-
ated with increased prescription coverage in the full cohort.
Table 2 Pre- versus during-SMS program differences in prescription coverage
Full Cohort,
N = 2255
<100% Baseline Coverage Subset,
N = 725
Recent ART Initiators Subset,
N = 416
Covariate Adjusted Odds Ratio (95% CI); P-value
Age (per year) 1.03 (1.01–1.04); P < 0.001 1.02 (1.01–1.03); P = 0.001 1.03 (1.01–1.06); P = 0.016
Female gender 1.55 (1.26–1.90); P < 0.001 1.32 (1.03–1.68); P = 0.027 0.92 (0.54–1.56); P = 0.751
Prior ART duration (per 30 days) – – –
Prescription length (per 30 days) 1.28 (1.27–1.29); P < 0.001 1.17 (1.16–1.19); P < 0.001 1.31 (1.28–1.34); P < 0.001
First line regimen 2.70 (2.33–3.12); P <0.001 4.30 (3.62–5.11); P < 0.001 5.52 (3.92–7.77); P < 0.001
Fixed dose combination 2.71 (2.62–2.81); P < 0.001 3.51 (3.33–3.70); P < 0.001 2.88 (2.67–3.10); P < 0.001
During-program period 0.61 (0.56–0.66); P < 0.001 1.56 (1.42–1.71); P < 0.001 0.53 (0.45–0.63); P < 0.001
Pre-program period coverage (by Group):
Exposed vs. Unexposed 1.05 (0.79–1.39); P = 0.732 1.00 (0.72–1.39); P = 0.992 2.53 (1.11–5.77); P = 0.028
Unknown vs. Unexposed 1.60 (1.02–2.51); P = 0.040 1.48 (0.85–2.57); P = 0.166 3.07 (1.01–9.35); P = 0.049
Program Effect (= During-program period coverage, by Group, adjusting for the variables above):
Exposed vs. Unexposed 1.23 (1.13–1.34); P < 0.001 1.29 (1.17–1.43); P < 0.001 1.17 (0.97–1.42); P = 0.101
Unknown vs. Unexposed 0.47 (0.41–0.54); P < 0.001 0.67 (0.57–0.80); P < 0.001 0.33 (0.24–0.45); P < 0.001
This table presents output from the mixed effects logistic regression on prescription coverage for a given day. The Groups are as follows: “Exposed” patients were
sent the SMS; “Unexposed” patients did not have mobile phone numbers and thus were not sent SMS; “Unknown” patients had unknown phone number statuses
due to missing charts, and thus also were not sent SMS. The “<100% Baseline Coverage Subset” includes patients with coverage < 100% in the pre-program
period. The “Recent ART Initiators Subset” includes patients who initiated ART within 2 years of the SMS program start. The backward stepwise selection process
of model parameters led to the omission of prior ART duration. CI = confidence interval. Bold indicates statistical significance at P < =0.05
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The subset of patients with <100% baseline coverage
consisted of 576, 104, and 45 patients for the Exposed,
Unexposed, and Unknown groups, respectively. The
baseline characteristics for the Exposed and Unexposed
subgroups did not demonstrate any statistically signifi-
cant differences; the Unknown subgroup differed from
the others in having a lower prevalence of first line regi-
men use at study baseline (84.4% compared to 95.0 and
92.3% for the Exposed and Unexposed, respectively) and
a higher proportion of missing data (8.9% compared to
0.4 and 1.0% for the Exposed and Unexposed, respectively).
The subset of patients who initiated ART within two years
of the SMS program start date consisted of 333, 41,
and 42 patients for the Exposed, Unexposed, and
Unknown groups, respectively. There were no statistically
significant differences in the baseline covariates among
these groups (data not shown).
For the <100% baseline coverage subset, the SMS pro-
gram was associated with an increase in prescription
coverage when comparing the Exposed and Unexposed
subgroups (AOR 1.29, 95% CI: 1.17–1.43, P < 0.001).
The corresponding absolute risk reduction of exposure
to the SMS program for an Exposed patient with average
coverage in this subset was 8.2 days of ART prescription
coverage missed per year compared to the Unexposed
group. For the recent ART initiator subset, no statisti-
cally significant differences were seen in prescription
coverage between the Exposed and Unexposed sub-
groups (AOR 1.17, 95% CI: 0.97–1.42, P = 0.101). Asshown in Table 2, increasing age, longer prescription
length, use of a first line regimen, and use of a fixed dose
combination were also associated with increased pre-
scription coverage in both subsets.
Discussion
This study assessed a weekly SMS program implemented
by a government-run clinic in rural South Africa with
limited outside funding, no incentives to encourage par-
ticipation, and no dedicated research staff, setting it
apart from prior research studies reported in the litera-
ture. Using routinely collected pharmacy data, we found
that a weekly SMS program had a positive effect on
ART adherence in a real world setting; however, the
magnitude of this effect was small (average of 4.7 days
per year). The effect for an average patient with <100%
baseline prescription coverage was 8.2 days per year, but
there was no significant effect for patients who had initi-
ated ART within two years of the SMS program, possibly
due to the relatively small size of the subset.
The clinical significance of the measured benefit of the
SMS program among the full cohort is unclear. Al-
though CD4 counts and viral loads were not consistently
available for comparison in this cohort, prescription
coverage has been shown to predict virologic suppression
[26]. Prescription coverage is conceptually the ceiling on
pill-taking adherence, the true value of which may be
lower than the measured prescription coverage. Moreover,
both the pattern and average level of adherence impact
clinical outcomes. Despite the relatively long half-life of
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Africa, increasing duration of treatment interruption,
even on the order of a few days, can increase risk of
viral rebound [27, 28].
Many of the recorded lapses in prescription coverage
may represent treatment interruptions, highlighting the
potential clinical significance of the measured program
effect. Future study of the downstream effects of real-
world SMS programs on viral suppression and other
clinical outcomes will help clarify the broader public
health impact of such programs.
The exact mechanism of the improvement in prescrip-
tion coverage is not known, but may reflect perceptions
of social support and encouragement to remain in care.
SMS programs have generally been well-accepted, in-
cluding this one as described in a separate report [20].
Other studies involving qualitative assessments of SMS
adherence interventions have noted a sense of social
support through the messages [7, 29]. Compared to that
of the full cohort, the SMS program effect size was
possibly stronger among patients in the <100% baseline
coverage subset, who likely had missed at least one pre-
scription and/or appointment during their pre-program
period. Missed appointments have been found to initiate
a cascade of disengagement from care [5], and the SMS
program’s mechanism could partially be via interruption
of this process. Notably, the SMS program did not show
a significant positive benefit among the recent ART initi-
ators subset, suggesting that the intervention’s effect is
not primarily via helping new patients to establish care.
The Unknown group (approximately 7% of the cohort)
had a disproportionate share of patients with adherence
challenges. It included patients whose charts were out-
side the file room during the period of data capture,
which generally indicated the presence of clinical chal-
lenges or being lost to follow-up. Given these aspects of
the Unknown group, we do not believe it is an unbiased
comparator to the Exposed group. These issues also
emphasize the importance of capturing phone numbers
at enrollment for all individuals in care to help to ensure
all vulnerable patients are offered the program.
While this study was not a randomized controlled trial,
we believe the Unexposed group is a reasonable compara-
tor to the Exposed group and adds value in assessing the
impact of the SMS program on ART adherence. One po-
tential source of confounding is differential phone owner-
ship in the Unexposed group, which was not assessed at
the time of the SMS program implementation. Rather,
patients were asked for their contact phone numbers at
clinic enrollment, which was on average 3.3 years prior to
SMS program launch. However, we believe this possibility
was unlikely to confound our results because, during this
time, the prevalence of mobile phone ownership among
South African adults was increasing and reached 90% in2013 [30]. Thus, we anticipate most of the patients in the
Unexposed group had mobile phones, but they were not
known to the clinic. We also believe patients were unlikely
to have withheld their phone numbers as another study
from an HIV clinic in the region (albeit one that charged
state-subsidized clinic fees) found that 99% of individuals
with cell phones were willing to be contacted by the clinic
on these phones [31]. That study also showed that age
and employment were socio-economic factors associated
with mobile phone ownership [31]. In our study, we were
able to control for age. While we could not directly con-
trol for employment, we used the pre-program prescrip-
tion coverage and patient-level random intercept to adjust
for confounders of the effect of the SMS program on ART
prescription coverage.
This analysis has other limitations. First, the unit of ob-
servation of each day was powered to detect small effects.
We addressed the repeated measures aspect of this ap-
proach by using a mixed model. Second, the prescription
lengths were long (up to 6 months) relative to the observa-
tion time (up to about 12 months), thus limiting our ability
to identify lapses in prescription coverage. Third, any errors
in clinical data collection may have incorrectly identified
patients as non-covered, including patients who transferred
out but did not receive the appropriate documentation
from the clinic.Conclusions
We found that exposure to the clinical SMS program had a
small measurable clinical impact among the full cohort that
was possibly stronger among patients with imperfect pre-
program prescription coverage. Generalizability to similar
government ARTclinics in the region is likely high.
We believe three primary avenues of future work should
be pursued. First, additional studies should further explore
the mechanisms by which SMS programs affect adherence,
particularly their effects on social support [7, 29]. Second,
long-term follow-up studies on the durability of impact
would be informative for the return on investment in this
type of intervention. Third, additional cohort studies of
other clinical SMS programs should assess the reproduci-
bility of the results in routine clinical settings.
In light of the high overall adherence, the cost-
effectiveness of such implementations could be enhanced
by improving their designs and targeting enrollment to in-
dividuals at risk for adherence challenges.
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